Clinical Trial in Patients with Advanced Bile Duct Cancers

What we are studying

The purpose of this study is to test the safety and effectiveness of an investigational drug called CPI-613 (“study drug”) when used to treat cholangiocarcinoma. CPI-613 is thought to kill cancer cells by turning off their mitochondria. Mitochondria are used by cancer cells to produce energy and are the building blocks needed to make more cancer cells. By shutting off these mitochondria, CPI-613 deprives the cancer cells of energy and other supplies that they need to survive and grow in your body. We want to find out what effects, good and/or bad, CPI-613 has on you and your cancer. We also want to measure the amounts of CPI-613 in your blood after it has been given to you.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosed with bile duct cancer of any type

What is involved

  • Screening visit
  • Ct scan
  • Administration of study drug

Compensation

Parking validation will be provided for all study-related visits.

Contact Information

Study Coordinator
Jennifer Ward Thomas
Email
[email protected]
Phone
-6914

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.